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iagnosing
cute Heart Failure
he Mathematician and the Clinician*
enneth Dickstein, MD, PHD*†
ogaland and Bergen, Norway
or giving us a glimpse of the inevitable future, Steinhart
t al. (1) deserve credit. In this issue of the Journal, the
uthors have created a mathematical diagnostic prediction
odel for assessing the likelihood of the presence of acute
eart failure (AHF) by combining clinical assessment and
easurement of N-terminal pro–B-type natriuretic peptide
NT-proBNP). Pre-test clinical assessment of the likeli-
ood of AHF and the NT-proBNP result are included in
he entered information. The model is explained well. It
valuates the clinical assessment as a categorical variable and
he NT-proBNP data as a continuous variable. The model
as validated internally against the adjudicated diagnoses in
34 patients from the IMPROVE-CHF (Improved Man-
gement of Patients With Congestive Heart Failure) study
2) and externally in data from 573 patients from the
RIDE (N-Terminal Pro-BNP Investigation of Dyspnea
n the Emergency Department) study (3). The article
emonstrates that the model has excellent diagnostic accu-
acy, especially in cases of intermediate clinical probability.
n these patients, the model appropriately reclassified the
ikelihood to either low or high probability of AHF with
egligible inappropriate redirection.
See page 1515
Let us get back for a moment to the emergency depart-
ent. What do clinicians do when a patient presents with
cute dyspnea? We observe the patient, interview the
atient and family, take a history, and perform a physical
xamination. We try to elicit symptoms suggestive of AHF,
etect signs indicating congestion, and search for objective
vidence of a structural or functional abnormality of the
eart at rest. Common cardiovascular and noncardiovascular
omorbidities that may contribute to the clinical symptoms
hould be identified. The initial routine investigations,
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.1
From the *Stavanger University Hospital, Stavanger, Rogaland, Norway; and the
Institute of Internal Medicine, University of Bergen, Bergen, Norway.hich usually include electrocardiogram, blood gases, chest
-ray, and hopefully echocardiography, are evaluated.
The patient’s response to initial management frequently
etermines subsequent treatment. When the laboratory data
rrive, we look for evidence of contributory factors such as
nemia, infection, renal dysfunction, or acute coronary
yndrome. If we are lucky, we get a natriuretic peptide level
uickly. We know that the levels of this biomarker contain
mportant diagnostic and prognostic information and the
reater the value, the more likely the diagnosis of HF. Often
he diagnostic workup and treatment algorithm will proceed
imultaneously.
The clinician will enter all of this information into his or
er cortex and assimilate it by a complex neurologic process
hat occurs on both conscious and subconscious levels.
xperience and knowledge will determine the success of the
peration, which represents a sophisticated biologic data-
anagement process that results in a prediction of the
ikelihood of the presence of AHF.
Why is diagnosing AHF so difficult? Most definitions of
HF emphasize the rapid-onset aspect of the symptoms
nd the need for urgent therapy (4), but it is a mixed bag of
atients. The etiologies are heterogeneous, with ischemic
eart disease and hypertension dominating, and mildly
levated troponins are frequently observed. The impact on
yspnea of comorbidities such as pulmonary disease, infec-
ion, anemia, or renal dysfunction can be challenging to
ssess. The fact that so many patients have a preserved
jection fraction, with or without objective findings that
uggest diastolic function, complicates confirmation of the
iagnosis. Much of the information we have in AHF is
ubjective, qualitative, and variable between patients and
ospitals. Obviously, clinical skills also may vary consider-
bly among physicians.
The data on natriuretic peptides have been collected from
eterogeneous patient cohorts. Studies have sampled natri-
retic peptides from patients presenting with increasing
yspnea to their primary care physician and to the hospital,
ncluding patients with known chronic heart failure who
ecompensate acutely or who present for the first time with
ew onset AHF. The data on this biomarker stem from
iverse groups. There is no consensus concerning cutoff
evels (5). The strongest documented evidence relates to the
egative predictive value; low levels of natriuretic peptides
ake the diagnosis of heart failure unlikely. However,
uring “flash” pulmonary edema, natriuretic peptide levels
ay remain normal at the time of admission.
Anecdotes sometimes are illustrative. A few weeks ago I
ecruited a patient admitted with acute dyspnea for an AHF
rial. He was 65 years of age with a rapid onset shortness of
reath over a few hours with no chest pain. He had a history
f a single uncomplicated anterior myocardial infarction and
ad been essentially asymptomatic. On admission we re-
orded sinus tachycardia, tachypnea, and a blood pressure of
80/95 mm Hg. His hemoglobin saturation was 88% on 2 l
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October 13, 2009:1522–3 Diagnosing Acute Heart Failuref oxygen in the emergency department. He had bilateral
ales half-way up the lung fields, and chest X-ray confirmed
ulmonary edema. The echocardiogram showed a good left
entricle with only mild left ventricular dilation and an
jection fraction of 45%. Two troponins were 0.05 g/l.
e was responding well to intravenous morphine, furo-
emide, nitroglycerin, and a continuous positive airway
ressure mask. He had just consented to participate in the
rial when the NT-proBNP appeared on the laboratory
creen. It was 150 pmol/l. The natriuretic peptide level was
oo low and he was therefore excluded from the trial. Alas,
lost my otherwise “perfect” patient.
The lack of objective criteria can make determination of
ample size and event rate in randomized clinical trials
ifficult. Inclusion of patients without AHF can dilute
reatment effect and potentially reduce the trial’s power to
etect the effect of intervention. Including BNP measure-
ent as an inclusion criterion would assure a cohort with a
ore certain diagnosis and greater number of cause-specific
nd points. There may well be a useful role for a mathe-
atical model in determining sample size for a randomized
linical trial. However, in clinical practice do we need an
nnovative diagnostic model that will integrate natriuretic
eptide levels with clinical evaluation?
What do we essentially need to know when evaluating a
atient with acutely progressive dyspnea? The critical clin-
cal question must be to determine whether there is pulmo-
ary congestion. Which is worse: to treat a patient for AHF
ho does not have heart failure or to delay treatment of a
atient with AHF? Delaying treatment is not a good
lternative, especially when initial management options
uch as oxygen, diuretics, morphine, and noninvasive ven-
ilation should not usually be detrimental in patients with-
ut AHF or pulmonary congestion. Clinicians charged with
he responsibility of managing a patient with acute dyspnea
hould be able to make a decision based on the history,
hysical examination, blood gasses, and chest X-ray.
The reader of the paper by Steinhart et al. (1) should be
ware of some important limitations. The most common
tiology in patients with AHF is an acute coronary syn-
rome. Those patients, as well as patients with infection,
bstructive airways disease, or moderate renal dysfunction
ere excluded from the 2 patient cohorts used to evaluate
he model. Such selected populations seriously limit the
pplicability of the results. Another major limitation con-
erns the “gold standard” diagnosis. Those of us who have porked on adjudication committees know how challenging
he process can be in AHF trials, and unanimous consensus
s not always easily obtained. The interested reader should
nderstand these deliberations in detail and know specifi-
ally what information was requisite for the final diagnosis
f AHF, especially so when the accuracy of a redirection for
he presence or absence of AHF is necessarily dependent on
ubjective adjudication. The strength of the continuous
odel as compared with one with multiple categories for
he predictors is not obvious. Is it not possible that several
ategories of pre-test estimated probability and NT-
roBNP levels might be as reliable as continuous variables?
t would certainly be easier to apply in practice.
Clinical skills are judged by our ability to collect, weigh,
nd correctly interpret all of the available information. I
elieve that we do evaluate all of this information in both
ategorical and continuous fashions. Someday a software
rogram will outperform a good clinician. It will be the end
f an era, but perhaps the dawn of a new epoch.
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tavanger University Hospital, Armauer Hansens vei 20,
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